Weak linkage in hepatitis C PePHD: identification of mutation prone point that can lead to failure of antiviral therapy for prevention of hepatocellular carcinoma.

Simple item page
dc.contributor.authorWiwanitkit, Virojen_US
dc.date.accessioned2009-05-27T17:52:24Z
dc.date.available2009-05-27T17:52:24Z
dc.date.issued2007-01-05en_US
dc.descriptionAsian Pacific Journal of Cancer Prevention.en_US
dc.description.abstractHepatitis C is an important blood borne infection caused by hepatitis C virus (HCV). Chronic inflammation induced by this viral infection and its role in carcinogenesis are well recognized. The treatment of HCV infection has developed enormously over recent years and is believed to be a good way for stopping of carcinogenesis process. However, mutation of the virus is an important factor that can bring drug resistance. Presently, prediction of protein nanostructure and function is a great challenge in the proteomics and structural genomics era. To identify points which are vulnerable to mutation is a new trend to expand the knowledge at the genomic and proteomic levels Here, the author performed a bioinformatic analysis to determine positions that trend to comply with peptide motifs in the amino acid sequence of HCV protein kinase -eIF2-alpha phosphorylation homology domain (PePHD). To identify weak linkage in HCV PePHD, a new bioinformatic tool, GlobPlot, was used. Positions 2-7, 29-39, 53-57, 90-98, 123-133, 202-227, 324-355, 439-448 were identified as positions resistant to mutation. Some are already known and others are newly discovered. Based on this study, weak linkages in HCV PePHD could be identified and can be good information for expectation of possible new mutations that can lead to failure of HCV therapy. In addition, the results from this study can be good information for further research on the diagnosis for mutants HCV and vaccine development.en_US
dc.description.affiliationDepartment of Laboratory Medicine, Chulalongkorn University, Bangkok, Thailand. wviroj@yahoo.comen_US
dc.identifier.citationWiwanitkit V. Weak linkage in hepatitis C PePHD: identification of mutation prone point that can lead to failure of antiviral therapy for prevention of hepatocellular carcinoma. Asian Pacific Journal of Cancer Prevention. 2007 Jan-Mar; 8(1): 139-40en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/38065
dc.language.isoengen_US
dc.source.urihttps://www.apocp.orgen_US
dc.subject.meshAntiviral Agents --pharmacologyen_US
dc.subject.meshCarcinoma, Hepatocellular --drug therapyen_US
dc.subject.meshComputational Biologyen_US
dc.subject.meshDrug Resistance, Viral --geneticsen_US
dc.subject.meshHepacivirus --drug effectsen_US
dc.subject.meshHepatitis C --drug therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver Neoplasms --drug therapyen_US
dc.subject.meshMutation --geneticsen_US
dc.subject.meshPhosphorylationen_US
dc.subject.meshProtein Structure, Tertiaryen_US
dc.subject.mesheIF-2 Kinase --chemistryen_US
dc.titleWeak linkage in hepatitis C PePHD: identification of mutation prone point that can lead to failure of antiviral therapy for prevention of hepatocellular carcinoma.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Asian Pacific Journal of Cancer Prevention